Evidence map›Paper›PMID 38422368›Full record

ArticleJournal of burn care & research : official publication of the American Burn Association2024

Bone and Skin/Subcutaneous Tissue Concentrations of Cefiderocol During Treatment of Extensively Drug-Resistant Pseudomonas aeruginosa.

Scott W Mueller, Kyle C Molina, Brittany Blass, Cameron Gibson, Amber D Kohler, Martin Krsak, Arek J Wiktor

Open access · hybridAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of burn care & research : official publication of the American Burn Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Scott W MuellerDepartment of Pharmacy, University of Colorado Hospital, Aurora, CO 80045, USA.
Kyle C MolinaDepartment of Emergency Medicine, University of Colorado Anschutz School of Medicine, Aurora, CO 80045, USA.
Brittany BlassDivision of GI, Trauma, and Endocrine Surgery (GITES), Department of Surgery, University of Colorado Hospital, Aurora, CO 80045, USA.
Cameron GibsonDivision of GI, Trauma, and Endocrine Surgery (GITES), Department of Surgery, University of Colorado Hospital, Aurora, CO 80045, USA.ORCID 0000-0001-7776-0268
Amber D KohlerDivision of GI, Trauma, and Endocrine Surgery (GITES), Department of Surgery, University of Colorado Hospital, Aurora, CO 80045, USA.
Martin KrsakDivision of Infectious Diseases, Department of Medicine, University of Colorado School of Medicine, Aurora, CO 80045, USA.ORCID 0000-0002-1746-7462
Arek J WiktorDivision of GI, Trauma, and Endocrine Surgery (GITES), Department of Surgery, University of Colorado Hospital, Aurora, CO 80045, USA.
University of Colorado Hospital · USUniversity of Colorado Anschutz Medical Campus · USUniversity of Colorado Denver · US

Funding

Shionogi, Inc. 22-0113-230683
6 · The paper itself

Abstract

Pyoderma gangrenosum is a rare dermatologic disorder that disrupts the skin barrier, requiring immunosuppressive therapy. We successfully used cefiderocol for the treatment of an extensively drug-resistant Pseudomonas aeruginosa bacteremia, and presumed osteomyelitis in a patient with severe pyoderma gangrenosum and associated immunosuppressive therapy while being medically optimized for skin grafting. We obtained bone and skin/subcutaneous tissue while the patient was on cefiderocol under an institutional review board-approved biologic waste recovery protocol. Cefiderocol concentrations in bone and skin/subcutaneous tissue were 13.9 and 35.9 mcg/g, respectively. The patient recovered from bacteremia and underwent autografting without further complications. Cefiderocol at approved dosing of 2 g IV (3-hour infusion) every 8 hours resulted in bone and skin/subcutaneous tissue concentrations adequate to treat extensively drug-resistant Gram-negative bacteria that remain susceptible to cefiderocol.

Indexed as

Anti-Bacterial AgentsCefiderocolCephalosporinsPseudomonas aeruginosaPseudomonas InfectionsPyoderma GangrenosumBacteremiaBone and BonesDrug Resistance, Multiple, BacterialHumansSkinSkin TransplantationSubcutaneous TissueAnti-Bacterial AgentsCefiderocolCephalosporinsbonecefiderocolconcentrationpenetrationskin/subcutaneous tissue

Identifiers

PMID38422368
PMCPMC11073579
OpenAlexW4392282360

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.